Introduction
============

Crohn's disease (CD) is a chronic inflammatory disease of the small and large intestine that results in significant morbidity, specifically the need for surgery. Despite advances in medical therapy, up to 70% of patients with CD will require surgery within 10 years of diagnosis.[@b1-ceg-9-237],[@b2-ceg-9-237] Surgical resection is not curative, and approximately 70% of patients will have endoscopic recurrence at 1 year. The overall clinical recurrence rates following surgery are 20% and 30% at 1 and 3 years, respectively, although they clearly differ based on the presence of endoscopic recurrence.[@b3-ceg-9-237]--[@b5-ceg-9-237] The most common surgical procedure for CD is bowel resection, specifically an ileocecectomy, occurring in 60%--70% of patients who require surgery.[@b6-ceg-9-237]--[@b8-ceg-9-237] Historically, patients were only treated for clinical recurrence following surgery. However, with novel CD therapies and a paradigm change to utilize treatment to alter the course of the disease, there is a clear role for treatment before clinical recurrence. This can occur as empiric treatment for high-risk patients or tailored treatment based on endoscopic recurrence. The intent of these strategies is to prevent clinical recurrence and subsequent need for further surgical intervention.

In this review, we outline the steps associated with the optimal care for postsurgical CD patients and review the evidence surrounding the available options in each step: risk stratification for postoperative recurrence, treating endoscopic recurrence to prevent clinical recurrence, monitoring for progression of disease, and achieving target-directed treatment goals. Although surgery for CD is a broad term, we will focus on ileocecal resections with an ileocolonic anastomosis, as the majority of literature is in this area. It is likely that these principles can be applied to other postoperative CD settings. There are three general strategies in the management of postoperative CD: 1) empiric treatment following surgery to prevent recurrence; 2) assessment and treatment of endoscopic recurrence to prevent clinical recurrence; and 3) treatment of clinical recurrence. Optimal treatment at this time should focus on preventing clinical recurrence and utilizing a combination of empiric treatment for high-risk individuals and routine assessment and treatment of endoscopic recurrence to prevent a clinical recurrence after surgery.

Risk stratification
===================

Following surgery for CD, the initial question is: Does the patient require empiric therapy to prevent endoscopic and clinical recurrence? This decision is ideally made prior to surgery and should be done in conjunction with the surgical team. There is currently no validated risk model or score to stratify patients postoperatively; thus, the decision to label a patient "high-risk" and start empiric therapy needs to be individualized, taking into consideration the prior CD history and patients' preferences. Consistently identified risk factors for both endoscopic and clinical recurrence include smoking,[@b9-ceg-9-237],[@b10-ceg-9-237] history of prior surgery or resection,[@b11-ceg-9-237],[@b12-ceg-9-237] perforating disease (defined as occurrence of bowel perforation, intra-abdominal fistulas, or inflammatory masses and/or abscesses, in accordance with the Montreal B3 classification for penetrating disease behavior, but does not include isolated perianal fistula),[@b13-ceg-9-237]--[@b15-ceg-9-237] and myenteric plexitis.[@b16-ceg-9-237]--[@b18-ceg-9-237] Other factors with supportive data and variable use in risk assessment models proposed thus far include length of resection,[@b19-ceg-9-237],[@b20-ceg-9-237] disease location (such as perianal disease),[@b19-ceg-9-237] and shorter disease duration.[@b21-ceg-9-237] Newly investigated risk factors that require further validation include microbiota diversity,[@b22-ceg-9-237],[@b23-ceg-9-237] type of anastomosis,[@b11-ceg-9-237],[@b24-ceg-9-237] histological disease[@b25-ceg-9-237] (including decreased lymphatic vessel density,[@b26-ceg-9-237] granulomas in mesenteric lymph nodes,[@b27-ceg-9-237] and CD8^+^ T-cells in blood and ileal mucosa[@b28-ceg-9-237]), and visceral fat area on computed tomography (CT)[@b29-ceg-9-237] ([Table 1](#t1-ceg-9-237){ref-type="table"}).

Various definitions of "high"-risk exist based on the number of risk factors present ([Table 2](#t2-ceg-9-237){ref-type="table"}). In the postoperative Crohn's endoscopic recurrence (POCER) randomized trial, which compared patients who received systematic endoscopy after surgery (active care) to no endoscopy (standard care), high-risk patients were defined as having one or more of the following risk factors: smoking, perforating disease, or previous resection.[@b30-ceg-9-237] Using these criteria, 83% of patients enrolled were high-risk. Unfortunately, the definition for "high-risk" is arbitrary and will remain so until a prospective validated prediction tool is developed. Regueiro[@b31-ceg-9-237] divides risk into three categories: low-risk includes those with CD duration \>10 years, a short stricture (\<10 cm), and first surgery; moderate risk includes patients with disease \<10 years duration, active inflammation, and intestinal narrowing, but without perforating or fistulizing disease or a history of multiple surgeries; and high risk as having perforating disease and history of previous surgery.[@b31-ceg-9-237],[@b32-ceg-9-237] Buisson et al[@b33-ceg-9-237] classify risk based on the European Crohn's and Colitis Organization definition of established risk factors for smoking, prior intestinal surgery, perforating disease behavior, perianal location of disease, and extensive small bowel resection.[@b34-ceg-9-237] In their model, patients are stratified by number of risk factors for initial medical therapy after surgery, resulting in a three-tiered risk model where no risk factors was considered low-risk, one risk factor was moderate risk, and greater than or equal to two risk factors was high risk. In our practice, we typically define high-risk as those with two or more of the confirmed risk factors listed in [Table 1](#t1-ceg-9-237){ref-type="table"}. However, this is not based on strong evidence, but rather our own experience and interpretation of the evidence. In many situations, we will discuss empiric therapy for patients with only one risk factor and choose to monitor patients with two or more risk factors closely. In general, as our practice evolves, we rely more on an early (within 6 months postoperatively) colonoscopy to identify endoscopic recurrence to tailor therapy, rather than just preoperative or operative risk factors. Cleary, this is an area with much variability that will require more research to guide our clinical practice.

Initial risk stratification is important, as empiric treatment should be tailored to the risk assessment. Models based on established risk factors can be used for guiding initial therapy; however, ultimately, therapy should be individualized based on specific patient characteristics and prior treatment history.

Empiric treatment for high-risk individuals
===========================================

Generally, patients who are high-risk (defined by the treating physician) are treated empirically to prevent recurrence of CD. Deciding what medication to start requires knowledge of the efficacy of each agent as well as the patient's personal history of CD therapy. Failure of a class of medications preoperatively does not necessarily mean that medication class cannot be used in the postoperative setting, although there should be a rationale for a retrial and close assessment to determine efficacy. Almost all classes of therapy for CD treatment have been studied for the prevention of postoperative recurrence. Newer medications such as vedolizumab and novel therapies such as fecal microbiota transplant (FMT) may provide more targeted and potentially safer approaches, although clinical data are not yet available.

Mesalamine
----------

Mesalamine agents are appealing, as they are low cost and have a favorable safety profile. In a meta-analysis, mesalamine was associated with a reduction in clinical recurrence in comparison to placebo (relative risk \[RR\] =0.60; 95% confidence interval \[CI\] =0.37--0.88) and a trend toward, although not statistically significant, reduction of endoscopic recurrence (RR =0.67; 95% CI =0.39--1.08).[@b35-ceg-9-237] This was similar to a prior meta-analysis that found decreased clinical as well as severe (Rutgeerts score ≥i3) endoscopic recurrence in patients on mesalamine in comparison to placebo, however, not a reduction in all endoscopic recurrence.[@b36-ceg-9-237] Given the lack of efficacy for preventing endoscopic recurrence, mesalamines should likely not be routinely used as empiric treatment.

Thiopurines
-----------

Azathioprine and 6-mercaptopurine are efficacious in reducing clinical and endoscopic recurrence of postoperative CD. In two trials comparing thiopurines to placebo, they reduced endoscopic recurrence, and pooled data revealed reductions in clinical and endoscopic recurrence.[@b36-ceg-9-237]--[@b38-ceg-9-237] In a meta-analysis of studies comparing thiopurines to mesalamine, both were equally effective at maintaining clinical remission; however, thiopurines were more effective at reducing endoscopic recurrence for the first year (RR =0.71).[@b39-ceg-9-237] However, in a randomized trial, 22% of participants had to stop thiopurines due to side effects or medication intolerance.[@b40-ceg-9-237] In a network meta-analysis, thiopurines were associated with reduced clinical (RR =0.36; 95% CI =0.17--0.63) and endoscopic (RR =0.33; 95% CI =0.13--0.68) recurrence.[@b35-ceg-9-237] Given this, thiopurines are likely beneficial in moderate- to high-risk patients who are able to tolerate them without significant side effects.

Probiotics
----------

Probiotics are an attractive option given the data that suggest that the microbiome is altered in disease recurrence, and they also have minimal side effects. However, there are limited data on their efficacy. One randomized trial of VSL\#3 in postoperative patients found a trend toward, but not statistically significant, reduction in endoscopic recurrence compared to placebo.[@b41-ceg-9-237] However, pooled data from randomized trials investigating various probiotic formulations failed to show any difference with regard to clinical or endoscopic recurrence.[@b36-ceg-9-237] At this time, there does not appear to be sufficient data to support the routine use of probiotics as empiric treatment for reducing the risk of recurrence.

Antibiotics
-----------

Nitroimidazole antibiotics can reduce the rate of clinical and endoscopic recurrence. Metronidazole was associated with a reduction in risk of clinical and endoscopic recurrence in a randomized clinical trial and systematic review,[@b36-ceg-9-237],[@b42-ceg-9-237] with a greater effect when used in combination with azathioprine in a randomized trial.[@b37-ceg-9-237] Ornidazole was also associated with reduced clinical and endoscopic recurrence risk.[@b43-ceg-9-237] However, the effects of antibiotics may be limited if therapy with another agent is planned, as the addition of metronidazole to azathioprine did not reduce the risk of endoscopic recurrence in a randomized pilot study.[@b44-ceg-9-237] In addition, there are also concerns about the tolerability and safety when used as long-term therapy. In the POCER trial, all patients were prescribed a 3-month course of metronidazole regardless of risk. Seventy percent of patients tolerated full-dose metronidazole, 8% tolerated a reduced dose, and 20% had to stop metronidazole due to intolerance.[@b30-ceg-9-237] However, a decision analysis model identified antibiotics as the most cost-effective prophylactic treatment for reducing clinical postoperative recurrence.[@b45-ceg-9-237] Therefore, if tolerated, routine treatment with a nitroimidazole antibiotic may be a reasonable approach for patients in the postoperative setting.

Anti-tumor necrosis factor
--------------------------

Anti-tumor necrosis factor (anti-TNF) therapy, specifically infliximab and adalimumab, is more effective than other therapies at reducing clinical and endoscopic recurrence. In meta-analyses of randomized controlled trials evaluating empiric drug therapy in postoperative patients, anti-TNF therapy was the most effective therapy in reducing clinical (RR or odds ratio \[OR\] of 0.04--0.36) and endoscopic (RR or OR of 0.01--0.16) recurrence.[@b35-ceg-9-237],[@b46-ceg-9-237],[@b47-ceg-9-237] In a network meta-analysis of 15 trials, anti-TNFs were associated with the largest reduction in endoscopic and clinical recurrence in comparison to thiopurines, mesalamine, and placebo.[@b48-ceg-9-237]

In addition to improved short-term outcomes compared to other therapies, anti-TNFs, in particular infliximab, have demonstrated long-term efficacy. In the PREVENT trial, a randomized trial of 297 patients comparing infliximab 5 mg/kg to placebo in the postoperative setting, there was a trend toward the primary end point of reduced clinical recurrence in infliximab-treated patients at weeks 76 and 104, although this was not statistically significant (*P*=0.097 and 0.098, respectively).[@b49-ceg-9-237] However, there was significantly less endoscopic recurrence in infliximab-treated patients in comparison to placebo (*P*\<0.001). Multiple other trials have demonstrated infliximab to be efficacious at 1 year,[@b50-ceg-9-237],[@b51-ceg-9-237] and long-term data at 2 and even 5 years demonstrated reduced endoscopic recurrence, longer time to recurrence, and less need for additional surgery.[@b52-ceg-9-237] In addition to endoscopic remission, one pilot study found that infliximab prevented histologic recurrence of CD compared to azathioprine at 1 year.[@b53-ceg-9-237]

Adalimumab appears to be effective to a similar degree as infliximab. In pilot and retrospective analyses, adalimumab was effective at reducing clinical and endoscopic recurrence at rates comparable to infliximab.[@b54-ceg-9-237]--[@b56-ceg-9-237] An analysis of POCER data found that adalimumab was more effective at reducing endoscopic recurrence than thiopurines.[@b57-ceg-9-237] In a randomized trial of 51 patients comparing adalimumab, azathioprine, and mesalamine, adalimumab was associated with reduced clinical and endoscopic recurrence.[@b58-ceg-9-237]

On the basis of the available data, anti-TNFs appear to be the most efficacious for reducing both clinical and endoscopic recurrence, and thus are likely indicated in high-risk patients, especially those who are unable to tolerate thiopurines. However, there are concerns about the cost of anti-TNFs. Cost-effectiveness models did not demonstrate intravenous anti-TNFs to be cost-effective at 1 year postoperatively.[@b45-ceg-9-237],[@b59-ceg-9-237] Notably, injectable anti-TNFs were not included in this analysis because there was insufficient data at that time. Finally, an anti-TNF may not be the ideal therapy if the patient was on an anti-TNF preoperatively. A retrospective analysis of 57 patients revealed that exposure to two or more anti-TNFs prior to surgery was associated with higher rates of endoscopic and clinical recurrence.[@b60-ceg-9-237] While not an absolute contraindication for anti-TNF therapy, the decision to use an anti-TNF in the postoperative setting must take into consideration prior anti-TNF use and the reason for cessation. Likely, the reason for prior anti-TNF failure will predict the benefit of retreatment in the postoperative setting.[@b61-ceg-9-237]

Combination therapy
-------------------

Combination therapy in CD typically refers to the concomitant use of a thiopurine and an anti-TNF. In treatment naïve CD, this combination of medications is clearly superior to monotherapy at inducing and maintaining remission.[@b62-ceg-9-237] However, following surgery, it is not clear why two immunosuppressive medications are needed. In a retrospective analysis of 41 patients, the addition of azathioprine to infliximab was correlated with the continuation of infliximab treatment, suggesting there may be benefit in reducing immunogenicity to infliximab.[@b63-ceg-9-237] In a separate retrospective analysis of 168 patients, there was no difference in endoscopic recurrence within 12 months after surgery in patients treated with anti-TNF monotherapy or anti-TNF plus thiopurine combination therapy.[@b64-ceg-9-237] This limited data suggest monotherapy with an anti-TNF is likely sufficient and an immunomodulator may be used to decrease the immunogenicity in certain patients.

Other drug combinations have also been studied in the postoperative setting. Two studies have evaluated the combination of azathioprine for 1 year and metronidazole for 3 months in comparison to metronidazole monotherapy or azathioprine monotherapy. D'Haens et al[@b37-ceg-9-237] found a reduction in endoscopic recurrence with the addition of azathioprine for 1 year to metronidazole for 3 months in comparison to metronidazole for 3 months alone. Manosa et al[@b44-ceg-9-237] did not find a difference in endoscopic recurrence in patients on azathioprine for 1 year, regardless of whether metronidazole for 3 months was added. Thus, the addition of metronidazole appears unlikely to have a benefit when the patient is already on an immunomodulator. The Adalimumab on Preventing Postsurgical Recurrence on Crohn's Disease (APPRECIA) study is a randomized trial comparing metronidazole plus azathioprine to metronidazole plus adalimumab, and it has not been published yet (NCT01564823).

Timing of empiric therapy
-------------------------

The optimal timing of initiating therapy is not entirely clear as trials have shown mixed results when comparing systematic empiric therapy versus endoscopy-driven treatment. However, early initiation after surgery (within 4 weeks) has been advocated for high-risk patients given the high rate of endoscopic recurrence and the association with future clinical recurrence, while low-risk patients may benefit from close endoscopic monitoring at 6 months and treatment based on endoscopic findings. Two studies suggest initiating therapy later may not have an adverse effect on outcomes. A retrospective analysis of postoperative CD patients did not identify a difference in endoscopic, clinical, or surgical recurrence in patients started on therapy early (\<4 weeks) or late (\>4 weeks) postoperatively.[@b65-ceg-9-237] However, the late group was treated more commonly with anti-TNFs than the early group. In another retrospective analysis of 199 patients, clinical recurrence rates were lower in patients treated with immediate postoperative therapy versus therapy driven by endoscopy within 6 months of surgery on univariate analysis, however, not on multivariate analysis when controlled for length of follow-up.[@b66-ceg-9-237] In the authors' opinion, when the decision to treat empirically is made, therapy should be initiated within 2--4 weeks after an uncomplicated surgery so as to prevent early endoscopic inflammatory changes. It is essential that the decision be made in conjunction with the surgical team to ensure the safety of this approach.

Postoperative therapeutic drug monitoring
-----------------------------------------

Similar to the preoperative setting, in the postoperative setting serum drug concentrations are associated with endoscopic and clinical response. For treatment of endoscopic recurrence, a post hoc analysis of a randomized trial found that higher 6-thioguanine levels were associated with endoscopic improvement in patients with severe postoperative endoscopic recurrence.[@b67-ceg-9-237] Similarly, median adalimumab trough levels were lower in patients with clinical or endoscopic recurrence in another post hoc analysis.[@b68-ceg-9-237] Two trials of proactive infliximab concentration monitoring have demonstrated improved remission rates and a longer duration of infliximab use with monitoring.[@b69-ceg-9-237],[@b70-ceg-9-237] In both instances, approximately 40% of the study population consisted of postoperative CD patients, and there was a clinical benefit in monitoring infliximab concentrations. Although prospective studies specific to postoperative CD need to be performed, these data suggest that optimizing an anti-TNF to a therapeutic concentration will improve the outcomes for postoperative CD patients similarly to preoperative ones.

Dosing anti-TNFs based on drug concentration may also allow for lower doses in the postoperative setting. In this case, the bulk of inflammation is surgically removed, which likely decreases the metabolism and/or stool loss of the anti-TNF.[@b71-ceg-9-237] In a prospective cohort study of twelve patients, low-dose infliximab (3 mg/kg) was effective at maintaining endoscopic remission at 1 year.[@b72-ceg-9-237] In a small comparison study of a subset of five of those patients on low-dose infliximab (3 mg/kg) compared to patients on standard dosing (5 mg/kg), all remained in endoscopic remission at 30 months after surgery.[@b73-ceg-9-237] Thus, therapeutic concentrations of an anti-TNF may be able to be achieved at a lower dose, while on the other hand, low concentrations could be a surrogate marker for disease recurrence and increased drug turnover. Given that the inflammatory burden is lower in the postoperative setting, and fecal losses of anti-TNFs are presumably minimized, deescalation of anti-TNF dose based on trough concentration is an appealing strategy that has not been directly studied.

Tailored treatment for endoscopic recurrence
============================================

Detecting recurrent disease
---------------------------

### Endoscopy

Identifying endoscopic recurrence and tailoring therapy to prevent clinical recurrence is becoming the standard of postoperative care for lower risk patients. Detecting endoscopic recurrence is important because it can predict clinical recurrence as well as separate out recurrent CD from noninflammatory causes of diarrhea, such as infections, bile salt diarrhea, and bacterial overgrowth, as symptoms may correlate poorly to inflammation.[@b74-ceg-9-237] Endoscopy is currently the gold standard for diagnosis of recurrent disease, and ileal recurrence can be defined based on the Rutgeerts score:[@b5-ceg-9-237] i0 -- no lesions, i1 -- less than or equal to five aphthous lesions, i2 -- greater than five aphthous lesions with normal intervening mucosa, i3 -- diffuse aphthous ileitis with diffusely inflamed mucosa, i4 -- diffuse inflammation with large ulcers, nodules, and/or narrowing. A score of i2 or greater is considered endoscopic recurrence. Recurrent mucosal disease after surgery precedes clinical symptoms, and its severity predicts subsequent clinical disease.[@b5-ceg-9-237],[@b75-ceg-9-237]

Capsule endoscopy may be useful as an adjunctive imaging study that was relatively equal to endoscopy findings in a recent review and may detect lesions missed by or unreachable with endoscopy.[@b76-ceg-9-237] However, capsule endoscopy has only been studied in small patient numbers and likely should only be used to assess for recurrence when endoscopy is contraindicated or unable to reach the surgical anastomosis. Given the poor predictability of clinical symptoms for endoscopic recurrence, and the invasiveness and cost of endoscopy, there has been interest in using surrogate testing, such as imaging and biomarkers, to monitor for disease recurrence.

### Imaging

Various imaging modalities hold promise as noninvasive methods for detecting postoperative recurrence, including CT, magnetic resonance imaging (MRI), and ultrasound. Enterography, either by CT or MRI, is both sensitive and specific for recurrent CD.[@b77-ceg-9-237]--[@b79-ceg-9-237] Deciding between either test is based on concern for repeated ionizing radiation and the local radiologic expertise. Enteroclysis (standard, CT, or MRI) is also sensitive, specific, and accurate compared to endoscopy, although it is time and labor intensive and likely has little role if CT or MRI enterography is available.[@b80-ceg-9-237]--[@b82-ceg-9-237] Other imaging techniques, such as ultrasonography, have demonstrated promise in research settings, but lack widespread clinical expertise at this time.[@b83-ceg-9-237] Imaging can be quite helpful as a noninvasive marker of disease and provides additional information of other areas of the bowel. However, given the well-validated use of the Rutgeerts score and the ability to take biopsies, we prefer endoscopy when able to assess initial postoperative recurrence.

### Biomarkers

Serum and fecal biomarkers have been studied as surrogate markers for inflammation in CD, and in the postoperative setting, may play an important role in detecting recurrence and selecting patients for endoscopy. Fecal calprotectin (FC) levels correlate with endoscopic findings in CD before surgery, and their utility in monitoring for endoscopic recurrence has recently become of interest. In multiple small studies utilizing different FC cutoffs postoperatively, levels were associated with endoscopic activity.[@b84-ceg-9-237]--[@b86-ceg-9-237] In a meta-analysis of ten studies with 613 patients with FC measured postoperatively, the pooled sensitivity and specificity for detecting endoscopic recurrence were 0.82 (95% CI =0.73--0.89) and 0.61 (95% CI =0.51--0.71), respectively, and positive and negative likelihood ratios were 2.11 (95% CI =1.68--2.66) and 0.29 (95% CI =0.197--0.44), respectively.[@b87-ceg-9-237] In a prospective observational study, FC levels were significantly higher in patients with endoscopic recurrence, with a negative predictive value of 93% at a cutoff of \<100 μg/g, which per the authors would have resulted in 30% fewer endoscopies in their cohort.[@b88-ceg-9-237] An analysis of data from the POCER trial found that FC levels correlated with endoscopic recurrence, whereas serum C-reactive protein (CRP) and Crohn's disease activity index did not.[@b89-ceg-9-237] In this study, a cutoff of FC \>100 μg/g identified patients with endoscopic recurrence with 89% sensitivity and 58% specificity, and the negative predictive value of a FC of \<100 μg/g was 91%. Based on this cutoff, colonoscopy would not have been needed in 47% of patients without endoscopic recurrence, but with the tradeoff of missing 11% of patients with endoscopic recurrence.[@b90-ceg-9-237] Based on these studies, our practice is to correlate FC with endoscopy. If they correlate well, then FC can be used to monitor for future recurrence or response to therapy after an initial endoscopy.

Serum inflammatory markers, such as CRP, have also been studied as a biomarker for recurrence, however, without strong data in support of their efficacy in detecting recurrence. Small studies have not demonstrated a consistent correlation between CRP and endoscopic recurrence, potentially owing to the inflammatory disease burden in postoperative patients not being large enough to cause a significant elevation.[@b73-ceg-9-237],[@b74-ceg-9-237],[@b88-ceg-9-237] Based on the inconsistent data, CRP should not be used solely as a marker for monitoring recurrence.

Treating endoscopic recurrent disease: treating-to-target
---------------------------------------------------------

Treatment of endoscopic recurrence is important given the high rate of progression to clinical recurrence. Two studies have specifically addressed treatment of endoscopic recurrence. Sorrentino et al[@b91-ceg-9-237] investigated 24 patients with endoscopic recurrence treated with infliximab or mesalamine and showed that those treated with infliximab were more likely to be in endoscopic remission at 54 weeks (54% versus 0%). In a pilot study by Yamamoto et al,[@b92-ceg-9-237] patients treated with infliximab for endoscopic recurrence at 6 months postoperatively were more likely to have improved endoscopic inflammation and be in clinical remission as compared to azathioprine- or mesalamine-treated patients.

The concept of "treat-to-target" has gained importance in treating CD, specifically targeting to endoscopic mucosal healing.[@b93-ceg-9-237] The main therapeutic target identified by the Selecting Therapeutic Targets in Inflammatory Bowel Disease program for CD was mucosal healing on ileocolonoscopy, with use of cross-sectional imaging only in patients who cannot be adequately assessed with ileocolonoscopy.[@b94-ceg-9-237] Serum and fecal markers of inflammation were not recommended targets, but instead adjunctive measures of inflammation to be used for monitoring.

Recent studies in postoperative patients have focused on adopting a treat-to-target strategy, specifically targeting endoscopic mucosal healing on systematic surveillance endoscopy postoperatively, and proactively stepping up therapy when endoscopic healing is not achieved. One retrospective study of patients who underwent systematic endoscopy and step-up therapy based on endoscopic findings revealed reduced clinical recurrence rates in those who underwent systematic endoscopy in comparison to those who did not.[@b95-ceg-9-237] Another retrospective study found patients with endoscopic recurrence who were treated with step-up in therapy were less likely to have subsequent clinical recurrence.[@b96-ceg-9-237] In a small prospective trial, no difference was seen in patients who received systematic azathioprine therapy versus endoscopy-driven therapy.[@b97-ceg-9-237] However, this trial was ended early due to low recruitment. In the POCER study, patients were treated initially based on the risk of recurrence and randomized to receive colonoscopy at 6 months postoperatively or no colonoscopy. Patients who received systematic colonoscopy and were treated with step-up therapy based on endoscopic findings had reductions in further clinical and endoscopic recurrence at 18 months after surgery.[@b30-ceg-9-237] Based on these trials, a treat-to-target strategy should be the standard of care in treating postoperative CD patients. Currently, the optimal target is endoscopic healing, requiring surveillance endoscopy at regular intervals after surgery.

Future therapies
================

Potential upcoming areas of investigation for prevention and treatment of postoperative recurrence include newer pharmacologic agents, such as vedolizumab and ustekinumab, as well as treatments aimed at altering the microbiota, such as FMT. Vedolizumab is a gut-specific anti-integrin monoclonal antibody approved for the treatment of CD and ulcerative colitis and may be beneficial in the postoperative setting given its ability to reduce leukocyte trafficking in the gut and theoretically reduce early inflammatory changes.[@b98-ceg-9-237]--[@b100-ceg-9-237] However, as of this writing, there are no studies assessing the use of vedolizumab to prevent endoscopic recurrence. FMT is currently being investigated in a clinical trial as an option for prevention of endoscopic recurrence (NCT02417974). The rationale behind FMT as a therapeutic modality stems from the benefit of antibiotics in postoperative CD, the fact that bacterial exposure via fecal stream is needed for recurrence, and divergent microbial diversity in patients with and without recurrence.[@b22-ceg-9-237],[@b23-ceg-9-237],[@b101-ceg-9-237]

Putting it into practice and future directions
==============================================

When a patient with CD undergoes surgery, the treating physician must first determine if they plan to empirically treat postoperatively to prevent recurrence or wait and assess for endoscopic recurrence and then treat. Empiric treatment should be individualized and incorporate prior failed therapy, the efficacy of the drug in the postoperative setting, and the cost of therapy. There is no one correct answer for prevention of recurrent disease, and this decision must be individualized. We recommend treatment based on initial risk assessment ([Figure 1](#f1-ceg-9-237){ref-type="fig"}). We define high-risk patients based on having two or more of what we feel have been identified as the most consistent risk factors in the literature: smoking (OR =2.0), perforating disease (OR =1.5), prior resection (OR =1.8), and mesenteric plexitis (OR =1.9).[@b102-ceg-9-237] However, we acknowledge that our risk stratification scheme is arbitrarily defined based on our opinion and not prospectively validated, underscoring the need for individualized assessment, as well as a standardized risk stratification tool. In all circumstances, smoking cessation must be strongly encouraged in all patients given its significant association with increased risk of clinical and endoscopic recurrence. If the decision is made not to treat to prevent postoperative recurrence, then we strongly advise routine postoperative assessment for endoscopic recurrence and treatment of endoscopic recurrence to prevent clinical recurrence. If noninvasive markers correlate with endoscopy, they can be used for monitoring; however, at this time, endoscopy remains the gold standard for assessing for endoscopic recurrence. Similar to prevention, the exact choice of treatment for endoscopic recurrence is unknown, but likely, the efficacy of treatment options mirrors that for clinical recurrence in CD patients who have not previously undergone surgery. We do not advise waiting for clinical recurrence in the postoperative setting. Regardless of the initial choice, any intervention (prevention or treatment) should be routinely assessed for efficacy at 6--12 months with ileocolonoscopy. Current monitoring is suboptimal, as O'Connor et al[@b103-ceg-9-237] reported in a retrospective analysis that 22.4% of patients had no endoscopic or radiologic evaluation of their disease over the course of a 32-month follow-up period, and only 42.8% of patients had postoperative colonoscopies. Among those who did, the average time to follow-up was 58 weeks.

Although we have progressed substantially in our understanding and management of postoperative CD, many challenges still remain. At this time, there is no validated clinical tool to risk-stratify an individual's postoperative risk of recurrence. Such a tool would be very helpful in determining who to empirically treat following surgery versus who to survey for endoscopic recurrence and subsequently treat if present. Additionally, our understanding of biomarkers for disease recurrence is incomplete. Although FC is promising, determining exact cutoffs and prospective validation is needed before widespread use. Similarly, the exact role of various imaging modalities will need to be determined as well as assessed for cost-effectiveness compared to endoscopy. Therapeutic drug monitoring may allow for lower doses of anti-TNFs to be effectively utilized in the postoperative setting. Finally, novel therapies such as lymphocyte trafficking inhibition or FMT may ultimately be more effective at preventing recurrent disease. Although many uncertainties remain, clinicians treating postoperative CD should attempt to risk-stratify all patients for postoperative recurrence before surgery and have a clear plan in place following surgery, including routine assessment for disease recurrence, regardless of the initial empiric treatment strategy.
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![Early postoperative management following surgery for Crohn's disease.\
**Notes:** The exact definition of high-risk is not standardized; however, we typically define high-risk as having two or more risk factors included in the "high-risk" box shown in the figure. Initiation of medical therapy is largely determined on the patient's prior history. Anti-TNFs are the most efficacious therapy for preventing endoscopic and clinical recurrence.\
**Abbreviation:** TNFs, tumor necrosis factors.](ceg-9-237Fig1){#f1-ceg-9-237}

###### 

Risk factors for endoscopic and clinical recurrence after surgery for Crohn's disease

  Confirmed risk factors   Probable risk factors   Investigational risk factors
  ------------------------ ----------------------- ------------------------------
  Smoking                  Shorter disease         Genetic mutations
  Perforating disease      duration                Histological disease factors
  Previous surgery         Disease location        Imaging findings
  Myenteric plexitis       Extent of disease       Microbial diversity
                           Granulomas              Type of anastamosis

###### 

Models for defining patients at high-risk for postoperative Crohn's disease recurrence proposed by various authors

  Model                                   Characteristics of high-risk patients
  --------------------------------------- -------------------------------------------------------------------------------------------------------------------
  De Cruz et al (2015)[@b30-ceg-9-237]    One or more of: smoking, perforating disease, or previous resection
  Vaughn et al (2014)[@b102-ceg-9-237]    Two or more of: smoking, perforating disease, previous resection, or myenteric plexitis
  Regueiro et al (2009)[@b31-ceg-9-237]   Perforating disease or history of multiple surgeries
  Buisson et al (2012)[@b33-ceg-9-237]    Two or more of: smoking, previous resection, perforating disease, perianal location, or extensive bowel resection
